Antihypertensive drugs slow the progressive decline used to estimate the transition rates for each stage from the onset of renal failure until death. All direct in renal function seen in patients with insulindependent diabetes and nephropathy. In a recent costs were discounted by an annual rate of 6%, and were subjected to sensitivity analysis. The disstudy, the ACE inhibitor captopril protected against this deterioration in renal function. We developed counted cost saving of ACE inhibitor treatment for a cohort of 1000 patients was estimated as £0.95 an economic model to analyse the cost impact of ACE inhibitor treatment on progression to endmillion over 4 years. Under sensitivity analysis, these results were very robust to variations in the costs stage renal failure (ESRF) in diabetic patients over 4 years. Two scenarios were compared: one describof ESRF treatment. Prophylactic treatment with ACE inhibitors was predicted to provide substantial ing the progression of a cohort of 1000 patients receiving 25 mg captopril three times daily, and the increases in life expectancy and reduction in the incidence of ESRF, while also providing significant other for an equivalent cohort without such prophylactic treatment. Previously published data were economic savings.
Introduction
Diabetic nephropathy is a relatively common microreplacement therapy (RRT), and diabetic nephropathy is the cause in nearly one-fifth of them.4 In the US, vascular complication of both insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent the total cost of caring for diabetic patients with renal failure approached US$2 billion in 1989, and diabetes mellitus (NIDDM), and poses a major threat to survival and quality of life in people with diabetes. 1 continues to rise rapidly.5 Many other costs are not included in this total, such as the cost of most outIt is clinically defined by the presence of persistent proteinuria in a diabetic patient with concomitant patient drugs, and lost production. Table 1 outlines the major direct and indirect costs of diabetic nephroretinopathy and elevated blood pressure, but without urinary-tract infection, other renal disease, or heart pathy to society.6 Patients with diabetic nephropathy almost invarifailure. 2 In established diabetic nephropathy, glomerular filtration rate declines relentlessly towards endably suffer from raised arterial blood pressure.2 A progressive rise in blood pressure occurs with declinstage renal failure (ESRF), necessitating dialysis or transplantation in many cases.
ing renal function.7 Treatment of hypertension has been shown to slow the rate of loss of renal function, Studies in the UK have indicated that approximately 600 new cases of ESRF occur in diabetic and several studies have used angiotensin-converting enzyme (ACE) inhibitors.2 patients every year (about 10 cases per million population).3 Throughout the world, over half a
The Diabetic Nephropathy Collaborative Study Group (DNCSG) carried out a trial to determine million patients are registered as being on renal We have developed an economic model using the results of the DNCSG to simulate the likely long-
The model starts with a cohort of patients with term outcome of ACE inhibitor treatment in IDDM diabetic nephropathy8 ( Figure 1 , box 1). The user patients with nephropathy. Our aim was to estimate can select an initial cohort size (for example, 1000) the effectiveness of ACE inhibitor treatment in terms or the size of the population to be considered. In of survival and the need for kidney transplantation, the latter case, the model calculates the size of the and also to assess the cost savings and benefits by cohort from the incidence rates of diabetic considering all direct costs of medical care. We nephropathy. compared two simulated cohorts of patients with Some patients in the initial cohort will go on to diabetic nephropathy, one cohort treated prophydevelop ESRF (box 2). It is this progression that was lactically with an ACE inhibitor (25 mg captopril delayed by prophylactic treatment with an ACE three times daily) and the other not so treated.
inhibitor. Progression rates to ESRF and death for patients treated with and without the ACE inhibitor were taken from a similar study carried out in the US,
Methods
which derived these figures from the DNCSG trial data.9 In the subsequent analysis, it was assumed Figure 1 shows the treatment paths used in the economic model for a simulated group of patients that 10% of those who develop ESRF will not be treated because of major comorbidities, and will die with diabetic nephropathy, from the development of ESRF to death. The model covers a period of 4 within a short period of time.
The majority of patients who are recommended years, the duration of the DNCSG trial.8 The group of patients were aged 18-49 years, had had IDDM for ESRF treatment will be assessed to determine their suitability for kidney transplant (box 3). We for at least 7 years, with an onset before the age of 30 years, and had diabetic retinopathy.8 Comorbid have assumed that this assessment may include an echocardiogram (90%), cardiac consultation (30%), conditions included in the model are not shown in Figure 1 , and are discussed later.
and cardiac catheterization (15%).
As a result of the transplant assessment, some an annual cost of £249. Costs for GP care and patients will be on dialysis and waiting for a suitable cardiology treatments, and procedures included in transplant to become available (box 4), whilst others the model, were taken from 'Costing of Cardiology will be on permanent dialysis (box 5). For costing Services',11 which also gives more detail of the purposes, the model includes the three most common costing methodology. modes of dialysis in the UK: hospital (35%), home (5%), and continuous ambulatory peritoneal dialysis Indirect costs and savings (CAPD, 60%).10 Over a period of two and a half
In this analysis, only direct costs have been incorporyears, up to 35% of patients will receive a kidney ated. Indirect costs, such as loss of working capacity transplant (box 6). However, 15% of patients waiting due to dialysis, or benefits such as increased fitness for a transplant die annually.10 for work (see Table 1 ) have been omitted. This has Patients whose transplants fail (box 7) are categorbeen done for two reasons. Firstly, the indirect costs ized into 'early' and 'late' graft failures according to whether the transplant failed in the first year postare notoriously difficult to quantify and are, at best, transplant, or subsequently. This allows different subjective. Secondly, the paper is written from survival parameters to be used for early and late an NHS perspective, and the only relevant costs in graft failure patients, to take account of the average such a context are direct NHS costs. However, from additional life years already enjoyed by late graft a community standpoint, the use of direct costs and failure patients.10 Some patients who survive a transsavings in these calculations probably underestimates plant failure will be regrafted, although it is extremely the true benefit of prophylactic treatment. rare for a diabetic patient to have more than two grafts, the maximum assumed in the model.
Discounting
All costs and benefits have been discounted by 6%
Comorbidities per year to take into account the general preference Comorbid conditions are included in the model as to incur costs in the future rather than in the average incidence or prevalence rates for a group of present.12 patients. The probabilities were derived from literature where possible, or clinical judgement was used.
Sensitivity analysis
Comorbidities where the same rates were used for all A sensitivity analysis was performed by varying key patients include diabetic retinopathy, and ketoacidosis parameters to investigate the effect of uncertainties or hypoglycaemic episodes. Different rates were used in the data on the results of the study. The sensitivity for patients before progression to ESRF, on dialysis, or post-transplant, for peripheral vascular disease of the direct cost savings achieved by treating patients (ulcers and amputations) and cardiovascular events with an ACE inhibitor was examined in relation to and conditions (stroke, angina, myocardial infarction, the two key study parameters-the rates of progrescongestive heart failure, and revascularization).
sion of the two cohorts to ESRF and death, and the difference in the costs of care for diabetic care alone compared with the costs of treating ESRF.
Treatment
Typical treatment pathways for diabetic nephropathy
Further program details
in the UK were used in the model. Most of the data relating to dialysis and transplants were obtained Further details of the program used to make the from the Report of the Review of the London Renal calculations can be obtained from the York Health Services,10 which is based mainly on UK and Economic Consortium. European EDTA data. The long-term survival rates of patients with diabetic nephropathy may be underestimated, as data from 1978 onwards were used to Results achieve reasonable sample sizes, and survival rates The annual costs of treating different patient groups, are likely to have improved since then.
as well as the total costs for each cohort, were calculated.6 The total cost over 4 years for a cohort Drug treatment and specific procedure of 1000 patients treated with an ACE inhibitor was costs £8 334 500 compared with £9 287 300 for the untreated group (Table 2) . This shows an immediate Costs for procedures and other hospital treatments saving of £952 800 on direct costs, equivalent to a were obtained from a variety of hospitals in England.
saving of £953 per patient. Drug costs were derived from published NHS
In the first year, the cost of the cohort of ACE sources,11 ACE inhibitor treatment being costed on the basis of 25 mg captopril three times daily, giving inhibitor patients is greater than the untreated cohort, due to the additional cost of the treatment itself (£977 700 over 4 years). However, by the second year, the medical benefits of reducing the number of patients developing ESRF are reflected in the reduced costs of care ( Figure 2 ). The costs saved in not having to treat so many patients for ESRF more than compensate for the cost of the ACE inhibitor and the costs of treating the extra patients kept alive. Figure 3 shows the costs of caring for ESRF patients, either with transplants or with dialysis, relative to the cost of diabetic care alone. The cost of caring for a patient on dialysis is over 18 times the cost for diabetic care alone, at approximately £23 000 per year. This economic model can also be used in 'population mode' to establish the cost consequences of treating diabetic patients with nephropathy for a given popufor IDDM patients starting renal replacement therapy13 and data from the Lewis trial of the lation. The incidence of diabetic nephropathy in the UK has been estimated using EDTA figures percentage of patients with diabetic nephropathy reaching Table 3 , using the UK population and illustrated population sizes of small districts The key variable in this economic analysis was the ratio of the cost of treating patients for ESRF (200 000) and large districts (500 000) in the model to calculate discounted cost savings and life years compared with that of treating patients for diabetes alone. A sensitivity analysis was done by leaving the saved. These figures indicate the savings arising from each cohort of patients entering the model each year.
costs of diabetic care constant and underestimating the costs of all procedures and treatment for ESRF These are treatment costs for the number of patients developing diabetic nephropathy in any by 10% and 20%; and also overestimating the costs by 10% and 20%. year, over the following four years, and can also be interpreted as the total costs for four successive It can be seen that even if the costs of ESRF treatment have been overestimated by 20%, there is cohorts in any one year. a resultant cost saving using ACE inhibitor therapy of £517 200 over 4 years (Figure 4) . If the ESRF costs
Sensitivity analysis
have been underestimated by 20%, the cost saving The calculated progression rates to ESRF and death over 4 years is increased to almost £1.4m. appear erratic from year to year, presumably as a result of the relatively small number of patients with diabetic nephropathy affected. Two issues of relevDiscussion ance are: how the costs of treating either cohort are affected by the timing of progression to ESRF, and
The DNCSG has shown that ACE inhibitor therapy protects against deterioration in renal function in the confidence limits on the overall progression rates over the four years.
insulin-dependent diabetic nephropathy, and is significantly more effective than blood pressure control Regression lines were fitted to each of the cumulative progression rates to ESRF and death. The result alone over a period of four years.8 ACE inhibitor treatment was also associated with a 50% reduction of smoothing these progression rates was to increase slightly the costs of both the ACE-inhibitor-treated in risk of the combined endpoints of death, dialysis, and transplantation that was independent of a small group and the untreated group. However, the absolute cost saving for the ACE-inhibitor-treated cohort disparity in blood pressure between the groups. In this study, the cost saving of prophylactic treatof 1000 patients over four years is increased to £1.0m, but the life years saved are reduced very ment with an ACE inhibitor over 4 years for an initial cohort of 1000 has been estimated as £0.95m, slightly from 195 to 191.
Proportional-hazards regression analysis was used with 195 life-years saved. For the UK population (58.4 m), this represents a cost saving of almost to estimate the 95%CIs of the risk reduction for death/ESRF in the DNCSG study.8 These CIs were £400 000 per year. As indirect costs were not considered in this analysis, total cost savings would probably applied to the cumulative progression rates, using the untreated group results as a baseline. In the worst be even greater. Sensitivity analysis has shown that the most pessimistic scenario from the trial results, of case, if a risk reduction of only 18% is assumed (compared with the trial result of 50%), a cost of only 18% reduction in risk progression to death or ESRF, would still yield 52 life-years saved at a cost £71 000 is incurred over 4 years and 52 life-years are saved; the cost per life-year saved is £1360. The of £71 000. The results are robust to variations in the costs of ESRF treatment. upper 95%CI (70%) on risk reductions suggests a cost 
